Skip to content

Pemetrexed Disodium for Injection

DRUG8 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., BeBetter Med Inc, Shanghai Hengrui Pharmaceutical Co., Ltd., Nanjing Leads Biolabs Co.,Ltd

Conditions

Advanced Solid TumourAdvanced Urothelial CarcinomaEGFRMetastatic Cervical CancerNSCLC (Advanced Non-small Cell Lung Cancer)NSCLC Patients With Brain MetastasisNon Small Cell Lung CancerPD-L1 Positive Non-small Cell Lung Cancer

Phase 1

Phase 2

Phase 3

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)
NCT04203485
Jiangsu HengRui Medicine Co., Ltd.PD-L1 Positive Non-small Cell Lung Cancer
Start: 2020-06-15End: 2022-05-31Target: 762Updated: 2020-05-08
A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma
RecruitingNCT06738251
Shanghai Hengrui Pharmaceutical Co., Ltd.Advanced Urothelial Carcinoma
Start: 2025-02-12End: 2027-09-30Target: 402Updated: 2025-07-17
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
RecruitingNCT06956001
Allist Pharmaceuticals, Inc.EGFR, NSCLC (Advanced Non-small Cell Lung Cancer)
Start: 2024-11-19End: 2028-07-01Target: 300Updated: 2026-02-12
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
RecruitingNCT06970639
Allist Pharmaceuticals, Inc.NSCLC Patients With Brain Metastasis
Start: 2024-09-26End: 2029-09-01Target: 380Updated: 2026-02-12
A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
Not yet recruitingNCT07418749
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Metastatic Cervical Cancer, Recurrent Cervical Cancer
Start: 2026-03-01End: 2028-12-01Target: 398Updated: 2026-02-18

Related Papers